UBX — Unity Biotechnology Income Statement
0.000.00%
Last trade - 00:00
- $25.18m
- -$18.02m
- 22
- 35
- 20
- 15
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 4.78 | 0.236 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 89.7 | 93.9 | 61.2 | 57.6 | 45.2 |
Operating Profit | -89.7 | -93.9 | -56.5 | -57.4 | -45.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -82.2 | -93.8 | -60.7 | -44.5 | -39.9 |
Net Income After Taxes | -82.2 | -93.8 | -60.7 | -44.5 | -39.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -82.2 | -93.8 | -60.7 | -44.5 | -39.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -82.2 | -93.8 | -60.7 | -44.5 | -39.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -18.8 | -17.9 | -10.9 | -4.5 | -2.24 |